Basil T. Darras

Active 1987–2025

126
Papers
18,012
Citations
71
h-index
120
i10-index

Citations

Citations per year for Basil T. Darras1971: 1 citations1988: 8 citations1989: 8 citations1990: 15 citations1991: 20 citations1992: 18 citations1993: 17 citations1994: 13 citations1995: 16 citations1996: 8 citations1997: 4 citations1998: 6 citations1999: 6 citations2000: 4 citations2001: 12 citations2002: 26 citations2003: 16 citations2004: 13 citations2005: 10 citations2006: 21 citations2007: 16 citations2008: 20 citations2009: 23 citations2010: 23 citations2011: 28 citations2012: 31 citations2013: 41 citations2014: 49 citations2015: 61 citations2016: 51 citations2017: 145 citations2018: 193 citations2019: 698 citations2020: 965 citations2021: 1,047 citations2022: 829 citations2023: 652 citations2024: 1,196 citations2025: 432 citations2026: 16 citations1972–1987: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,483 citing papers, 26.8% of this breakdownUnited Kingdom: 577 citing papers, 10.4% of this breakdownItaly: 424 citing papers, 7.7% of this breakdownGermany: 343 citing papers, 6.2% of this breakdownCanada: 268 citing papers, 4.8% of this breakdownFrance: 260 citing papers, 4.7% of this breakdownChina: 211 citing papers, 3.8% of this breakdownNetherlands: 211 citing papers, 3.8% of this breakdownAustralia: 161 citing papers, 2.9% of this breakdownBelgium: 153 citing papers, 2.8% of this breakdownSwitzerland: 142 citing papers, 2.6% of this breakdownJapan: 141 citing papers, 2.5% of this breakdown
0%26.8%Other 21%

Fields

  • Medicine52.8%
  • Biochemistry, Genetics and Molecular Biology39.5%
  • Neuroscience4.6%
  • Engineering0.7%
  • Immunology and Microbiology0.4%
  • Computer Science0.4%
  • Other1.6%

Topics

  • Neurogenetic and Muscular Disorders Research15.5%
  • Muscle Physiology and Disorders9.2%
  • RNA modifications and cancer4.9%
  • Cardiomyopathy and Myosin Studies4.2%
  • RNA Research and Splicing3.6%
  • Amyotrophic Lateral Sclerosis Research3.5%
  • Other59.1%

Coauthors

All papers

Open in search
  1. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy

    Authors: , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 cited by 2,272

  2. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy

    Authors: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 cited by 1,424

  3. Spinal muscular atrophy

    Authors: , , , , - Nature Reviews Disease Primers 2022 cited by 415

  4. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , - The Lancet Neurology 2021 cited by 480

  5. Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls

    Authors: , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 274

  6. Risdiplam in Type 1 Spinal Muscular Atrophy

    Authors: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 419

  7. Revised upper limb module for spinal muscular atrophy: Development of a new module

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Muscle & Nerve 2016 cited by 362

  8. Natural history of infantile‐onset spinal muscular atrophy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Vicki L. McGovern, Xueqian Wang, Phillip G. Zaworski, Thomas W. Prior, Arthur H.M. Burghes, Amy Bartlett, John T. Kissel - Annals of Neurology 2017 cited by 409

  9. Observational study of spinal muscular atrophy type I and implications for clinical trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Neurology 2014 cited by 526

  10. Results from a phase 1 study of nusinersen (ISIS-SMN Rx ) in children with spinal muscular atrophy

    Authors: , , , , , , , , - Neurology 2016 cited by 602

  11. Neurofilament as a potential biomarker for spinal muscular atrophy

    Authors: , , , , , , , , , , , , , , , , - Annals of Clinical and Translational Neurology 2019 cited by 207

  12. Nusinersen in later-onset spinal muscular atrophy

    Authors: , , , , , , , , , , , , , , , , - Neurology 2019 cited by 260

  13. An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients

    Authors: , , , , , , , , , , , , , , , - Neuromuscular Disorders 2007 cited by 391

  14. Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - BMC Neurology 2017 cited by 221

  15. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nancy L. Kuntz, Adnan Manzur, Basil T. Darras, Peter B. Kang, Leslie Morrison, Monika Krzesniak‐Swinarska, Jean K. Mah, Tiziana Mongini, Federica Ricci, Maja von der Hagen, Richard S. Finkel, Kathleen O’Reardon, Matthew Wicklund, Ashutosh Kumar, Craig M. McDonald, Jay J. Han, Nanette C. Joyce, Erik Henricson, Ulrike Schara‐Schmidt, Andrea Gangfuß, Ekkehard Wilichowski, Richard J. Barohn, Jeffrey Statland, Craig Campbell, Giuseppe Vita, Gian Luca Vita, James F. Howard, Imelda Hughes, Hugh J. McMillan, Elena Pegoraro, Luca Bello, W. Bryan Burnette, Mathula Thangarajh, Taeun Chang - JAMA 2022 cited by 123

  16. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Armin Koch, Irina Balikova, Inge Joniau, Geraldine Accou, Valentine Tahon, Sylvia Wittevrongel, Elke De Vos, Rodrigo de Holanda Mendonça, Ciro Matsui, Ana Letícia Fornazieri Darcie, Cleide Machado, Maria Kiyoko Oyamada, Joyce Martini, Graziela Jorge Polido, Juliana Rodrigues Iannicelli, Juliana Caires de Oliveira Achili Ferreira, Chaoping Hu, Xiaomei Zhu, Qian Chen, Li Shen, Hui Li, Yiyun Shi, Shuizhen Zhou, Ying Xiao, Zhenxuan Zhou, Sujuan Wang, Tian Sang, Cuijie Wei, Hui Dong, Yiwen Cao, Jing Wen, Wenzhu Li, Lun Qin, Nina Barišić, Ivan Celovec, Martina Galiot Delić, Petra Kristina Ivkić, Nenad Vukojević, Ivana Kern, B Najdanović, Marin Skugor, Josipa Tomas, Odile Boespflug‐Tanguy, Silvana De Lucia, Andrea Seferian, Emmanuel Barreau, Nabila Mnafek, Helene Peche, Allison Grange, Diem Trang Nguyen, Darko Milaščević, Shotaro Tachibana, Emanuela Pagliano, Stefania Bianchi Marzoli, Diletta Santarsiero, Myriam Garcia Sierra, Gemma Tremolada, Maria Teresa Arnoldi, M. E. F Viganó, Claudia Dosi, Riccardo Zanin, Veronica Schembri, Noemi Brolatti, Giuseppe Rao, Elisa Tassara, Simone Morando, Paola Tacchetti, Marina Pedemonte, Enrico Priolo, Lorenza Sposetti and 72 more - The Lancet Neurology 2022 cited by 104

  17. Validation of the Expanded Hammersmith Functional Motor Scale in Spinal Muscular Atrophy Type II and III

    Authors: , , , , , , , , , , , , , , , - Journal of Child Neurology 2011 cited by 204

  18. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lindsay N. Alfano, Michelle Eagle, M. James, Linda Lowes, Anna Mayhew, Elena Mazzone, Leslie Nelson, Kristy Rose, Hoda Abdel‐Hamid, Susan Apkon, Richard J. Barohn, Enrico Bertini, Clemens Bloetzer, Lausanne Canton de Vaud, Russell J. Butterfield, B. Chabrol, Jong‐Hee Chae, Daehak-ro Jongno-gu, Giacomi Pietro Comi, Basil T. Darras, Jahannaz Dastgir, Isabelle Desguerre, Raúl G. Escobar, Erika Finanger, Michela Guglieri, Imelda Hughes, Susan T. Iannaccone, Kristi Jones, Peter Karachunski, Martin Kudr, Timothy Lotze, Jean K. Mah, Katherine D. Mathews, Yoram Nevo, Julie Parsons, Yann Péréon, Alexandra Prufer de Queiroz Campos Araújo, J. Ben Renfroe, Maria Bernadete Dutra de Resende, Monique M. Ryan, Kathryn Selby, Gihan Tennekoon, Giuseppe Vita - The Lancet 2017 cited by 455

  19. Revised upper limb module for spinal muscular atrophy: 12 month changes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Muscle & Nerve 2019 cited by 150

  20. Prospective cohort study of spinal muscular atrophy types 2 and 3

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Neurology 2012 cited by 291

  21. Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)

    Authors: , , , , , , , , , , , , , , , , - Journal of Neuromuscular Diseases 2023 cited by 63

  22. Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening

    Authors: , , , , , , , , , , , , , , - Journal of Neuromuscular Diseases 2018 cited by 227

  23. Overturning the Paradigm of Spinal Muscular Atrophy as Just a Motor Neuron Disease

    Authors: , - Pediatric Neurology 2020 cited by 164

  24. Revised Recommendations for the Treatment of Infants Diagnosed with Spinal Muscular Atrophy Via Newborn Screening Who Have 4 Copies of SMN2

    Authors: , , , , , , , , , , , , , - Journal of Neuromuscular Diseases 2020 cited by 137